695 related articles for article (PubMed ID: 33462140)
21. T cell specific deletion of Casitas B lineage lymphoma-b reduces atherosclerosis, but increases plaque T cell infiltration and systemic T cell activation.
Vos WG; van Os BW; den Toom M; Beckers L; van Roomen CPAA; van Tiel CM; Mohapatra BC; Band H; Nitz K; Weber C; Atzler D; de Winther MPJ; Bosmans LA; Lutgens E; Seijkens TTP
Front Immunol; 2024; 15():1297893. PubMed ID: 38504977
[TBL] [Abstract][Full Text] [Related]
22. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors.
Lontos K; Wang Y; Joshi SK; Frisch AT; Watson MJ; Kumar A; Menk AV; Wang Y; Cumberland R; Lohmueller J; Carrizosa E; Boyerinas B; Delgoffe GM
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914208
[TBL] [Abstract][Full Text] [Related]
23. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1.
Ngiow SF; Young A; Jacquelot N; Yamazaki T; Enot D; Zitvogel L; Smyth MJ
Cancer Res; 2015 Sep; 75(18):3800-11. PubMed ID: 26208901
[TBL] [Abstract][Full Text] [Related]
24. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
[TBL] [Abstract][Full Text] [Related]
25. Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30
Hombach AA; Rappl G; Abken H
Mol Ther; 2019 Oct; 27(10):1825-1835. PubMed ID: 31331813
[TBL] [Abstract][Full Text] [Related]
26. PD1
Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
[TBL] [Abstract][Full Text] [Related]
27. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer.
Parriott G; Deal K; Crean S; Richardson E; Nylen E; Barber A
Immunology; 2020 Jul; 160(3):280-294. PubMed ID: 32144940
[TBL] [Abstract][Full Text] [Related]
28. TOX promotes the exhaustion of antitumor CD8
Wang X; He Q; Shen H; Xia A; Tian W; Yu W; Sun B
J Hepatol; 2019 Oct; 71(4):731-741. PubMed ID: 31173813
[TBL] [Abstract][Full Text] [Related]
29. Exosomes derived from exhausted CD8+ T cells impaired the anticancer function of normal CD8+ T cells.
Wang X; Shen H; He Q; Tian W; Xia A; Lu XJ
J Med Genet; 2019 Jan; 56(1):29-31. PubMed ID: 29997128
[TBL] [Abstract][Full Text] [Related]
30. Solid Tumor Microenvironment Can Harbor and Support Functional Properties of Memory T Cells.
Sullivan PM; Reed SJ; Kalia V; Sarkar S
Front Immunol; 2021; 12():706150. PubMed ID: 34867942
[TBL] [Abstract][Full Text] [Related]
31. Tumor Fibroblast-Derived FGF2 Regulates Expression of SPRY1 in Esophageal Tumor-Infiltrating T Cells and Plays a Role in T-cell Exhaustion.
Chen QY; Li YN; Wang XY; Zhang X; Hu Y; Li L; Suo DQ; Ni K; Li Z; Zhan JR; Zeng TT; Zhu YH; Li Y; Ma LJ; Guan XY
Cancer Res; 2020 Dec; 80(24):5583-5596. PubMed ID: 33093168
[TBL] [Abstract][Full Text] [Related]
32. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
33. Silencing the expression of Cbl-b enhances the immune activation of T lymphocytes against RM-1 prostate cancer cells in vitro.
Zhou SK; Chen WH; Shi ZD; Wang SP; Li L; Wen XF; Wang YM
J Chin Med Assoc; 2014 Dec; 77(12):630-6. PubMed ID: 25249301
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia-mediated down-regulation of miRNAs' biogenesis promotes tumor immune escape in bladder cancer.
Zhao Y; Shi Z; Hao Z; Zhou J; Han C; Li R; Lv Q; Liu Y; Liang C
Clin Transl Oncol; 2021 Aug; 23(8):1678-1687. PubMed ID: 33625672
[TBL] [Abstract][Full Text] [Related]
35. The role of the e3 ligase cbl-B in murine dendritic cells.
Wallner S; Lutz-Nicoladoni C; Tripp CH; Gastl G; Baier G; Penninger JM; Stoitzner P; Wolf D
PLoS One; 2013; 8(6):e65178. PubMed ID: 23762309
[TBL] [Abstract][Full Text] [Related]
36. Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer.
Chen C; Gu YM; Zhang F; Zhang ZC; Zhang YT; He YD; Wang L; Zhou N; Tang FT; Liu HJ; Li YM
Oncoimmunology; 2021 Mar; 10(1):1901434. PubMed ID: 33854821
[TBL] [Abstract][Full Text] [Related]
37. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
38. Targeting Cbl-b in cancer immunotherapy.
Augustin RC; Bao R; Luke JJ
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36750253
[TBL] [Abstract][Full Text] [Related]
39. In Vivo Generation of CAR T Cells Selectively in Human CD4
Agarwal S; Hanauer JDS; Frank AM; Riechert V; Thalheimer FB; Buchholz CJ
Mol Ther; 2020 Aug; 28(8):1783-1794. PubMed ID: 32485137
[TBL] [Abstract][Full Text] [Related]
40. Cbl-b gene silencing in splenic T lymphocytes as a therapeutic strategy to target the prostate cancer RM-1 cell tumors in immune competent mice.
Shi ZD; Li XF; Hao L; Zhao Y; Wang YX; Dong BZ; Chen WH; Zhang ZG; Wang YM; Fu Q; Han CH; Li S
Eur Rev Med Pharmacol Sci; 2014; 18(24):3819-30. PubMed ID: 25555872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]